Cardiovascular Clinical Consult

Latest News

CV risk
Empagliflozin Reduces Risk of CV Death, Hospitalization for Heart Failure With Preserved Ejection Fraction

July 8th 2021

The EMPEROR-Preserved study investigated empagliflozin (Jardiance; Eli Lilly) for the treatment of heart failure with preserved ejection fraction.

pharmacist in mask
Pharmacists Are Key Allies in Reducing Risk of Diabetes, Cardiovascular Disease

February 3rd 2021

cardiovascular disease
American Heart Association Report Predicts COVID-19 Effects on Cardiovascular Disease Burden

January 28th 2021

blood pressure
Study: Blood Pressure Medications Safe for Patients With COVID-19

January 22nd 2021

Heart failure medications
FDA Panel Votes on Expanded Use of Heart Failure Drug

December 17th 2020

More News

© 2023 MJH Life Sciences

All rights reserved.